Oppenheimer raised the firm’s price target on Harpoon Therapeutics (HARP) to $27 from $23 and keeps an Outperform rating on the shares. The firm notes that Merck (MRK) and Harpoon Therapeutics announced that the companies have entered into a definitive agreement under which the former will acquire the latter for $23/share in cash for a total equity value of $680M. Oppenheimer says in a research note titled “Could the takeout valuation be a starting point?” that it believes Harpoon’s novel T-Cell engagers are differentiated, the platform is scalable and the emerging early/late stage clinical data indicate a best-in-class asset.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HARP:
- M & A News: Merck (NYSE:MRK) to Acquire Harpoon for $680 Million
- Merck to acquire Harpoon Therapeutics for $23.00 per share in cash
- M & A: Merck (NYSE:MRK) Bolsters Oncology Portfolio With Harpoon Deal
- Harpoon Therapeutics initiated with an Outperform at Oppenheimer
- Harpoon Therapeutics Strengthens Leadership Team
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue